While an improvement in OS from the initiation of first-lime chemotherapy for HER2− ABC patients remains challenging, we successfully identified subgroups of HER2− ABC patients who had improved OS from the initiation of first-line chemotherapy that were treated with eribulin therapy. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.